
CLAIMS

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof;

wherein:

R_1 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocyclyl;

R_2 is hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocyclyl;

R_3 is unsubstituted C1-6 alkyl;


L is -C(Rb)(Rb)-, each Rb is independently hydrogen or C1-C6 alkyl, n is an integer of 0 to 3;

R_4 is halogen or substituted or unsubstituted heteroaryl or heterocyclyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R_1 is hydrogen, substituted or unsubstituted C1-6 alkyl; R_2 is hydrogen, substituted or unsubstituted C1-6 alkyl; Rb is hydrogen, n is an integer of 1 to 2; R_4 is heteroaryl optionally substituted with cyano, nitro, hydroxy, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, -C (O) Rd, -C (O) N (Re) (Rf), -C (O)O (Rd), -N (Re) (Rf), -OC (O) N (Re)(Rf), -OC (O) O(Rd), -OC(O)Rd, -S (O) $_{0-2}$Rd, -S(O) $_{0-2}$ ORd or -S (O) $_{0-2}$N (Re) (Rf); each Rd is independently hydrogen or C1-C6 alkyl; each Re and Rf is independently hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R_4 is a five- or six-membered heteroaryl containing 2-4 nitrogen atoms and is optionally substituted with cyano, nitro, hydroxyl, halo, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkyl.


4. A compound as shown in formula II:



(II)







wherein:











R_1 is hydrogen or C1-3 alkyl substituted or unsubstituted with halogen; R_2 is hydrogen, halogen, C1-6 alkyl unsubstituted or substituted with halogen or C1-6 alkoxy unsubstituted or substituted with halogen; X is CH_2, N, O or S; R_5 is selected from the group consisting of:





wherein R_6 is H, halogen, CN, CF3, NO2, C1-6 alkyl unsubstituted or substituted with halogen or C1-6 alkoxy unsubstituted or substituted with halogen.


5. A compound selected from the group consisting of:


,

,

,

,

,

,


O
N
N
CN
H
H
H
H
HO
H
,

O
N
H
H
H
H
HO
H
,

O
N
N
H
H
H
H
HO
H
,

N
N
O
N
N
H
H
H
H
HO
H
,

S
O
S
H
H
H
H
HO
H
,

O
N
N
N
N
H
H
H
H
HO
H
,

O
N
N
CN
H
H
H
H
HO
H
,

N
O
O
O
H
H
H
H
HO
H
,

N
O
S
O
H
H
H
H
HO
H
,

N
N
N
O
S
N
H
H
H
H
HO
H
,



, 

, and 

.

6. A pharmaceutical composition comprising a compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

7. Use of the compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of claim 6 in the preparation of a medicament for preventing or treating a neurological disease.

8. The use of claim 7, wherein the neurological disease is selected from the group consisting of sleep disorders, mood disorders, schizophrenia spectrum disorders, spastic disorders, memory disorders and/or cognitive disorders, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and truncation syndromes or tinnitus.

9. The use of claim 8, wherein the mood disorder is depression, wherein the depression is destructive mood disorder, severe depressive disorder, persistent depressive disorder, premenstrual dysphoric disorder, substance or drug induced disorder, or other specific depressive disorder and nonspecific depressive disorder.

10. The use of claim 8, wherein the neurological disease is mild depression, moderate depression, severe depression, or postpartum depression.

11. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is administered orally, subcutaneously, intravenously, or intramuscularly.